Alligator Bioscience Investor Relations Material
Latest events
Q4 2024
Alligator Bioscience
Access the full event backlog
Slides, Transcripts, and Reports from 12,000+ public companies
Latest reports from Alligator Bioscience
Access all reports
Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. Alligator’s portfolio includes several promising drug candidates, with the CD40 agonist mitazalimab as its key asset. Furthermore, Alligator is co-developing ALG.APV-527 with Aptevo Therapeutics Inc., several undisclosed molecules based on its proprietary technology platform, Neo-X-Prime™, and novel drug candidates based on the RUBY™ bispecific platform with Orion Corporation. Out-licensed programs include AC101/HLX22, in Phase 2 development, by Shanghai Henlius Biotech Inc. and an undisclosed target to Biotheus Inc.
Latest articles
)
eToro: Innovation, Growth, and IPO Plans
eToro was founded in 2007 and has grown into a global trading platform with over 40 million users and an extensive offering across several asset classes.
10 Apr 2025
)
Yum! Brands: The Company Behind Pizza Hut, KFC, and Taco Bell
Yum! Brands started at PepsiCo in the 1970s and is home to some of the most well-known brands in the world, such as Pizza Hut, KFC, and Taco Bell.
9 Apr 2025
)
Marvin Ellison: Chairman, President, and CEO of Lowe's
Marvin Ellison is CEO of Lowe's Companies, with over 30 years of experience in American retail and a career spanning leadership roles at major national chains.
9 Apr 2025
Ticker symbol
ATORX
Country
🇸🇪 Sweden